CSIMarket Company Name, Ticker, Suppliers, else..
 
Spero Therapeutics Inc   (NASDAQ: SPRO)
 
Price: $1.2100 $-0.01 -0.820%
Day's High: $1.2200000286102295 Week Perf: -0.82 %
Day's Low: $ 1.18 30 Day Perf: -4.72 %
Volume (M): 362,870 52 Wk High: $ 3.08
Volume (M$): $ 0 52 Wk Avg: $2.21
Open: $1.20 52 Wk Low: $1.08



 Market Capitalization (Millions $) 70
 Shares Outstanding (Millions) 58
 Employees 25
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 7
 Cash Flow (TTM) (Millions $) 25
 Capital Exp. (TTM) (Millions $) 0

Business Description


Spero Therapeutics Inc is a biopharmaceutical company focused on developing novel therapies to treat multi-drug resistant bacterial infections. The company utilizes its expertise in antimicrobial resistance and drug discovery to develop innovative antibiotics and combination therapies. Spero Therapeutics aims to address the urgent need for new treatments against drug-resistant bacteria, which pose a significant threat to global health. They are committed to developing safe and effective drugs that can combat these infectious diseases and improve patient outcomes.


   Company Address: 675 Massachusetts Avenue, Cambridge 2139 MA
   Company Phone Number: 242-1600   Stock Exchange / Ticker: NASDAQ SPRO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ        2.68% 
MRK        1.33% 
OGN        0.15% 
TEVA   -0.22%    
VRTX        0.82% 
VTRS        3.3% 
• View Complete Report
   



Clinical Study

Navigating New Frontiers Spero Therapeutics’ Tebipenem HBr and SPR720 TrialsInnovation Amidst Challenges

Published Tue, Oct 14 2025 3:58 PM UTC

Exploring Spero Therapeutics Recent Advancements and ChallengesSpero Therapeutics has been making waves in the pharmaceutical sector with its innovative drug candidates aimed at addressing serious bacterial infections and pulmonary diseases. Recent announcements regarding the company s lead antibiotic candidate, tebipenem HBr, and the investigational compound SPR720 have ...
Clinical Study

Spero Therapeutics Phase 1 Data on SPR720 Published Promising Results for Combatting Multidrug-Resistant Tuberculo...

Published Wed, Oct 2 2024 8:30 PM UTC

Spero Therapeutics Announces Significant Progress in Antibacterial Treatment with SPR720: Phase 1 Data Published in Antimicrobial Agents and ChemotherapySpero Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel treatments for bacterial infections, has made significant strides in its quest for effective therapies against multidrug-resistant p...
Shares

Spero Therapeutics Paves the Way for Innovation with Inducement Grant under Nasdaq Listing Rule

Published Wed, Jul 3 2024 5:05 PM UTC

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
In a recent press release, Spero Therapeutics, Inc. (Nasdaq: SPRO) announced that the Compensation Committee of the company s Board of Directors approved the grant of 227,500 restricted stock unit awards (RSUs) to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Ince...
Financing Agreement

Spero Therapeutics Announces Inducement Grant and Improved Financial Performance

Published Mon, Jun 3 2024 8:05 PM UTC


Spero Therapeutics, Inc. recently announced the approval of 116,667 restricted stock unit awards to a new employee as an inducement under the 2019 Inducement Equity Incentive Plan. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) and reflects the company s focus on identifying and developing novel treatments for rare diseases and multi-drug resistan...
Financing Agreement

Spero Therapeutics Empowers New Employee with Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published Wed, May 1 2024 8:08 PM UTC

CAMBRIDGE, Mass., May 01, 2024 - Spero Therapeutics, Inc. (Nasdaq: SPRO), a pioneering biopharmaceutical company specializing in the development of groundbreaking treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, revealed today that it has undertaken a momentous step in its journey. On April 29, 2024, the Compensation Committee of Spero s Boar...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 11.00
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.49
Price to Sales (Expected) -
Price to Book 1.59
PEG (TTM) -

Financial Strength Current
Quick Ratio 6.02
Working Capital Ratio 6.12
Leverage Ratio (MRQ) 0.19
Total Debt to Equity 0
Interest Coverage (TTM) -
Debt Coverage (TTM) 244.31

Per Share Current
Earnings (TTM) 0.11 $
Revenues (TTM) 0.81 $
Cash Flow (TTM) 0.43 $
Cash 0.88 $
Book Value 0.76 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) 295,320
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 12.57 %
Return On Investment (TTM) 14.88 %
Return On Equity (TTM) 16.17 %
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.